Articles related to KIDNEY DISEASE

SGLT-2 inhibitors offer benefits beyond glucose control, potentially addressing the systemic inflammatory components of metabolic diseases like diabetes, heart failure, and gout.

A recent randomized trial demonstrated that intravenous amino acid infusions can significantly reduce the incidence of acute kidney injury in patients undergoing cardiac surgery, highlighting a potential new approach to mitigating this common complication.

Semaglutide has been shown to reduce the risk of major kidney disease events and cardiovascular mortality in patients with type 2 diabetes and chronic kidney disease.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

Acquired reactive perforating collagenosis, characterized by pruritic eruptions and systemic associations, often manifests in patients with diabetes or chronic kidney disease, underscoring the necessity for holistic patient assessment in dermatological evaluations.

In patients with end-stage kidney disease, extraosseous calcification presents a complex clinical challenge, involving an active process with significant implications for patient management and outcomes. Understanding its pathogenesis and treatment options is crucial for optimizing care.